[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605795":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":20,"responsibleParty":40,"collaborators":11,"id":42,"slug":11,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":23,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Women's Hospital School Of Medicine Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"chemotherapy group","EXPERIMENTAL",null,[13],"Drug: Camrelizumab combined with chemotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Camrelizumab combined with chemotherapy","Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery",[9],[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Women's Hospital, School of Medicine, Zhejiang University","RECRUITING","Hangzhou","Zhejiang","310000","China",{"type":29,"coordinates":30},"Point",[31,32],120.16142,30.29365,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"Tingting Chen","CONTACT","86-13738102530","11318160@zju.edu.cn",{"type":41,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605795",false,"NCT07167160","Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial","Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;\n2. Positive PD-L1 expression;\n3. ECOG score ≤1\n\nExclusion Criteria:\n\n1. Positive parametrium or surgical margin;\n2. Incomplete radical surgery;\n3. Residual target lesions;\n4. Active autoimmune disease or autoimmune disease requiring systemic treatment;\n5. Previous treatment with immune checkpoint inhibitors.","FEMALE","18 Years","70 Years",{"count":52,"type":53},59,"ESTIMATED","INTERVENTIONAL",[56],"PHASE2","Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.",[59,60],"Cervical Cancer","Immunochemotherapy","2025-12-10",{"date":63,"type":64},"2025-12-18","ACTUAL",{"date":66,"type":64},"2025-03-10",{"date":68,"type":53},"2029-12-31",{"name":5,"class":6},1]